Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 7/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | MRGPRX1 | Q96LB2 | 6/20 | 0.34 |
| ▸ | TSPO | P30536 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1865309 | 0.99 | TLR4 (0.49) | TLR4METAP2MRGPRX1TSPOHRH1 | |
| SCHEMBL1864499 | 0.99 | TLR4 (0.49) | TLR4METAP2MRGPRX1TSPOHRH1 | |
| SCHEMBL1863669 | 0.99 | TLR4 (0.49) | TLR4METAP2MRGPRX1TSPOHRH1 | |
| SCHEMBL1863237 | 0.99 | TLR4 (0.49) | TLR4METAP2MRGPRX1TSPOHRH1 | |
| SCHEMBL1864523 | 0.99 | TLR4 (0.49) | TLR4METAP2MRGPRX1TSPOHRH1 | |
| SCHEMBL1864694 | 0.98 | TLR4 (0.51) | TLR4METAP2MRGPRX1TSPOHRH1 | |
| SCHEMBL1864334 | 0.94 | TLR4 (0.52) | TLR4METAP2MRGPRX1TSPOHRH1 | |
| SCHEMBL1868054 | 0.90 | TLR4 (0.48) | TLR4METAP2MRGPRX1TSPOHRH1 | |
| SCHEMBL1870713 | 0.90 | TLR4 (0.48) | TLR4METAP2MRGPRX1TSPOHRH1 | |
| SCHEMBL1866619 | 0.90 | TLR4 (0.48) | TLR4METAP2MRGPRX1TSPOHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935879-B1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-RE43858-E1 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-7935835-B2 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1935879-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | CD40, LITAF, TNF | TLR4 29/4885METAP2 1955/4885MRGPRX1 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.